So if we are to enjoy a robust sales period in CY23 is it necessary for the $3m shortfall to be put to the market? The entitlement offer expires on the 22nd of February; this time next week. The LBT Company Presentation slides of 20 January, 2023 boasts the first item as "$3.0m Non-dilutive funding secured expands APAS® market opportunity." Was BB suggesting the $3.0m Non-dilutive funds obviates the need to tap the Market for a Dilutive CR? Avoiding a 12% Dilution gets my vote. Pretty strong message to the Market, Shareholders and vested parties.
History tells me he will take the Cash.
GLTAH
So if we are to enjoy a robust sales period in CY23 is it...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.4¢ | $2.042K | 139.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1273383 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 127616 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| LBT (ASX) Chart |